RxDoctor Payments Data

Jeffrey Olson, DO

Family Medicine · Brodheadsville, PANPI 1669727913

Payments from drug & device makers

$1,774in general payments, 2019–2025

Across 90 payments — averaging $19.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$717
  • Novo Nordisk$225
  • Pfizer$176
  • Boehringer Ingelheim$175
  • Atricure, Inc.$162
  • AstraZeneca$74
  • plus $245 from 9 others

What the payments were for

  • Food & beverage$1,774100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,774 in reported general payments places this provider in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$62,058
Medicare patients
193
Services billed
681

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban79$66,679
JardianceEmpagliflozin66$60,494
OzempicSemaglutide53$58,792
MounjaroTirzepatide25$26,086
JanuviaSitagliptin Phosphate16$22,972
TrulicityDulaglutide20$20,072
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$15,708
Xultophy 100-3.6Insulin Degludec/Liraglutide14$14,677
Breo ElliptaFluticasone/Vilanterol15$6,559
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate17$6,030
Albuterol Sulfate HfaAlbuterol Sulfate136$4,874
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$3,657
Ventolin HfaAlbuterol Sulfate41$3,419
Atorvastatin Calcium278$2,644
Duloxetine Hcl41$2,390

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Xultophy 100-3.6$225$73,46967 claims
PfizerEliquis$176$66,67979 claims
Boehringer IngelheimJardiance$175$60,49466 claims
Lilly USA, LLCMounjaro, Trulicity$46$46,15945 claims
MerckJanuvia$40$22,97216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Brodheadsville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →